AAN Annual Meeting Programs: P4 - Poster Session 4 | American Academy of Neurology®

P4 - Poster Session 4

Event Time:	Wednesday May 8, 2019 11:30 am to 6:30 pm
Topic(s):	Practice, Policy, and Ethics, General Neurology, Aging, Dementia, Cognitive, and Behavioral Neurology, Cerebrovascular Disease and Interventional Neurology, Child Neurology and Developmental Neurology, Epilepsy/Clinical Neurophysiology (EEG), Headache, Infectious Disease, Movement Disorders, MS and CNS Inflammatory Disease, Neuroepidemiology, Neuromuscular and Clinical Neurophysiology (EMG), Research Methodology, Education, and History
Director(s):
Description:
Completion Message:
CME Credits:	0
Core Competencies:

Program Speakers - Tentative
Start/End Time	Title	Faculty
Currently there are no events in the timeline.

Disclosures
Speaker	Disclosure

Abstract Presenters
Movement Disorders ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	001	Substantia Nigra (SN) Hyperechogenicity is a Reliable Biomarker for Disease Progression From Stage I to Stage II in Early Onset Parkinson’s Disease (EOPD)	Disclosure: Dr. Ravi has nothing to disclose.
Migraine II
Start Time	Pub.	Title	Presenter
11:30 AM	001	A Randomized Trial of Telemedicine for Migraine Management	Disclosure: Dr. Friedman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder Biopharmaceuticals, Allergan, Amgen, Biohaven, electroCore, Eli Lilly, Promius, Revance, Supernus, Teva, Theranica and Zosano. Dr. Friedman has received personal compensation in an editorial capacity for Neurology Reviews. Dr. Friedman has received research support from Allergan, Autonomic Technologies, Inc (company entered into insolvency April 2019), Eli Lilly, Merck, Zosano.
Check Point Inhibitors and Paraneoplastic Neurological Disorders
Start Time	Pub.	Title	Presenter
11:30 AM	001	Neurologic Adverse Events associated with Immune Checkpoint Inhibitor Therapy	Disclosure: Dr. Duong has nothing to disclose.
Unusual Stroke Etiologies, Presentations and Treatments
Start Time	Pub.	Title	Presenter
11:30 AM	001	Mid-Atlantic Region State Ratios of Emergency Hyperbaric Chambers (EHC) to Comprehensive Stroke Centers (CSC) for Symptomatic Cerebral Air Embolus (SCAE)	Disclosure: Dr. Taylor has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	001	A case of aggressive motor neuron disease without profound loss of motor neuron cells	Disclosure: Dr. Liu has nothing to disclose.
Epilepsy: EEG and Neurophysiology
Start Time	Pub.	Title	Presenter
11:30 AM	001	Lack of Standardization of the Level of Encephalopathy on EEG: a Barrier to the Widespread Use of EEG for Brain Monitoring	Disclosure: Dr. Maciel has nothing to disclose.
Neuroepidemiology: ALS, MS, Parkinson's Disease and Epilepsy
Start Time	Pub.	Title	Presenter
11:30 AM	001	Clinical Characteristics of a Large Cohort of US Patients Enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010–2015	Disclosure: Dr. Raymond MPH has nothing to disclose.
Dystonia and Botulinum Toxin Therapy
Start Time	Pub.	Title	Presenter
11:30 AM	001	Muscle pattern changes in patients with cervical dystonia (CD) receiving botulinum toxin (BTX)	Disclosure: Dr. Gutflais has nothing to disclose.
NeuroHIV and other Retroviruses
Start Time	Pub.	Title	Presenter
11:30 AM	001	Cognitive Performance and Total and Regional Brain Volumes in Zambian Youth with HIV	Disclosure: Dr. Dean has nothing to disclose.
Aging and Dementia: Clinical Trials
Start Time	Pub.	Title	Presenter
11:30 AM	002	Baseline Characteristics from a Phase III Trial of Crenezumab in Early (Prodromal-to-Mild) Alzheimer’s Disease (CREAD)	Disclosure: Dr. Sink has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities as a full time employee of Genentech, Inc.
Movement Disorders ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	002	The Pseudodystonia: Important Pitfalls in the Diagnosis of Dystonia	Disclosure: Dr. Pan has nothing to disclose.
Migraine II
Start Time	Pub.	Title	Presenter
11:30 AM	002	Predictors of Non-Adherence with Acute Migraine Medications	Disclosure: Dr. Lofchie has nothing to disclose.
Check Point Inhibitors and Paraneoplastic Neurological Disorders
Start Time	Pub.	Title	Presenter
11:30 AM	002	Pembrolizumab-Associated Paraneoplastic Disorders: A Case Series	Disclosure: Dr. Gill has nothing to disclose.
Unusual Stroke Etiologies, Presentations and Treatments
Start Time	Pub.	Title	Presenter
11:30 AM	002	Unusual Cause of Acute Ischemic Stroke: A Case of Cerebral Air Embolism Post Transthoracic Lung Biopsy	Disclosure: Dr. Fahimi has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	002	Correlation between Slow Vital Capacity Measured in the Home and in the Clinic for Patients with Amyotrophic Lateral Sclerosis	Disclosure: Dr. Meng has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Cytokinetics employee.
Epilepsy: EEG and Neurophysiology
Start Time	Pub.	Title	Presenter
11:30 AM	002	The Sounds of Seizures: Audio-Triggered Detection by Convolutional Neural Network (CNN)	Disclosure: Dr. Basha has nothing to disclose.
Neuroepidemiology: ALS, MS, Parkinson's Disease and Epilepsy
Start Time	Pub.	Title	Presenter
11:30 AM	002	A comparison of the clinical and genetic features of Amyotrophic Lateral Sclerosis across Latin American and European populations	Disclosure: Dr. Hardiman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Wave Life Sciences, Cytokinetics, Treeway. Dr. Hardiman has received personal compensation in an editorial capacity for Taylor and Francis .
Dystonia and Botulinum Toxin Therapy
Start Time	Pub.	Title	Presenter
11:30 AM	002	Long-term outcomes of late deep brain stimulation in DYT1 dystonia	Disclosure: Dr. Ooi has nothing to disclose.
NeuroHIV and other Retroviruses
Start Time	Pub.	Title	Presenter
11:30 AM	002	Increased Caloric Intake is Associated with Lower Cognitive Scores in HIV-Positive Women	Disclosure: Dr. Warrior has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with John Redmond Esq.
Movement Disorders ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	003	Disruption of spermatogenesis and infertility in Ataxia with Oculomotor Apraxia Type 2 (AOA2)	Disclosure: Dr. Fogel has nothing to disclose.
Migraine II
Start Time	Pub.	Title	Presenter
11:30 AM	003	Rates of Associated Health Conditions in Those with Migraine vs. Non-migraine Controls: Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study	Disclosure: Dr. Buse has received personal compensation for consulting serving on a scientific advisory board speaking or other activities with Dawn Buse PhD has received honoraria from Allergan Amgen Biohaven Lilly Teva and Promius. Dr. Buse has received personal compensation in an editorial capacity for editorial board of Current Pain and Headache Reports. Dr. Buse has received research support from Amgen.
Check Point Inhibitors and Paraneoplastic Neurological Disorders
Start Time	Pub.	Title	Presenter
11:30 AM	003	Immune checkpoint inhibitor induced anti-GAD limbic encephalitis	Disclosure: Dr. Chung has nothing to disclose.
Unusual Stroke Etiologies, Presentations and Treatments
Start Time	Pub.	Title	Presenter
11:30 AM	003	A Rare Case of Air Embolus During Administration of tPA for Acute Ischemic Stroke	Disclosure: Dr. Southard has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	003	Survival prediction models in motor neuron disease	Disclosure: Dr. Spinelli has nothing to disclose.
Epilepsy: EEG and Neurophysiology
Start Time	Pub.	Title	Presenter
11:30 AM	003	Long-term Stability of Interictal Spike Trajectories in Pediatric Invasive EEG Recordings	Disclosure: Dr. Tomlinson has nothing to disclose.
Neuroepidemiology: ALS, MS, Parkinson's Disease and Epilepsy
Start Time	Pub.	Title	Presenter
11:30 AM	003	Incidence of Venous Thromboembolic Events Among Amyotrophic Lateral Sclerosis Patients in a US Health Insurance Claims Database	Disclosure: Dr. Kupelian has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen.
Dystonia and Botulinum Toxin Therapy
Start Time	Pub.	Title	Presenter
11:30 AM	003	Pilot feasibility study of a semi-automated three-dimensional scoring system for cervical dystonia	Disclosure: Dr. Oyama has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Medtronic, Boston Scientific, Otsuka Pharmaceutical, Sumitomo Dainippon Pharma, FP Pharmaceutical Corporation, and Kyowa Hakko Kirin, and Abbvie.
NeuroHIV and other Retroviruses
Start Time	Pub.	Title	Presenter
11:30 AM	003	Rare Case of Human T-lymphotropic Virus-1 (HTLV-1) with Amyotrophic lateral sclerosis	Disclosure: Dr. Khosa has nothing to disclose.
Aging and Dementia: Clinical Trials
Start Time	Pub.	Title	Presenter
11:30 AM	004	GeneMatch: A Novel Recruitment Registry using APOE Genotyping to Accelerate Referrals to Alzheimer’s Prevention Studies	Disclosure: Dr. Langbaum has received research support from Avid/Eli Lilly, Genentech/Roche, Novartis/Amgen.
Movement Disorders ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	004	A single ascending dose (SAD) study of a D1 receptor positive allosteric modulator (LY3154207) in healthy volunteers	Disclosure: Dr. Svensson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Svensson holds stock and/or stock options in Eli Lilly and Company.
Migraine II
Start Time	Pub.	Title	Presenter
11:30 AM	004	Undiagnosed Chronic Migraine Is Associated With Higher Economic Burden Compared With Diagnosed Chronic Migraine: Results From a Claims-Based Retrospective Study	Disclosure: Dr. Marcus has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan.
Check Point Inhibitors and Paraneoplastic Neurological Disorders
Start Time	Pub.	Title	Presenter
11:30 AM	004	Characterization of Encephalopathy Associated with Immune Checkpoint Inhibitor Therapy	Disclosure: Dr. Wei has nothing to disclose.
Unusual Stroke Etiologies, Presentations and Treatments
Start Time	Pub.	Title	Presenter
11:30 AM	004	A case of accidental ingestion of Hydrogen Peroxide causing massive cerebral gas embolic strokes	Disclosure: Dr. Bhattacharyya has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	004	Meta-analysis of Genetic Expression Profiles in Amyotrophic Lateral Sclerosis	Disclosure: Dr. Frank has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with uniQure, Oscine Therapeutics and Sage Therapeutics. Dr. Frank has received research support from Roche/Genentech and Vaccinex/Huntington Study Group.
Epilepsy: EEG and Neurophysiology
Start Time	Pub.	Title	Presenter
11:30 AM	004	EEG source localization comparing low-density EEG including subtemporal coverage with high density EEG	Disclosure: Dr. Danoun has nothing to disclose.
Neuroepidemiology: ALS, MS, Parkinson's Disease and Epilepsy
Start Time	Pub.	Title	Presenter
11:30 AM	004	Progression of Symptoms in relation to the Site of Onset in Amyotrophic Lateral Sclerosis: new Evidence supporting the Prion-like Hypothesis	Disclosure: Dr. Chio has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Cytokinetics, Roche. Dr. Chio has received research support from Italfarmaco.
Dystonia and Botulinum Toxin Therapy
Start Time	Pub.	Title	Presenter
11:30 AM	004	The Dystonia Coalition Natural History Project: Nine Years of Progress	Disclosure: Dr. Norris has nothing to disclose.
NeuroHIV and other Retroviruses
Start Time	Pub.	Title	Presenter
11:30 AM	004	Teriflunomide Reduces Spontaneous Lymphoproliferation of Peripheral Blood Mononuclear Cells From Patients With Human T-Lymphotropic Virus (HTLV)-1–Associated Myelopathy/Tropical Spastic Paraparesis	Disclosure: Dr. Akahata has nothing to disclose.
Aging and Dementia: Clinical Trials
Start Time	Pub.	Title	Presenter
11:30 AM	005	The Alzheimer Prevention Initiative Generation Program: Evaluation of CNP520 in Preclinical Alzheimer's Disease	Disclosure: Dr. Borowsky has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis and Teva.
Movement Disorders ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	005	Preliminary validation of a novel, comprehensive digital biomarker smartphone application to assess motor symptoms in recently diagnosed Parkinson patients	Disclosure: Dr. Lipsmeier has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with F. Hoffmann-La Roche Ltd.. Dr. Lipsmeier has received royalty, license fees, or contractual rights payments from F. Hoffmann-La Roche Ltd..
Migraine II
Start Time	Pub.	Title	Presenter
11:30 AM	005	Poor Acute Treatment Optimization and Frequent Nausea in Episodic Migraine (EM) are Associated with New Onset Chronic Migraine (CM): Results from 2017 Migraine in America Symptoms and Treatment (MAST) Study	Disclosure: Dr. Schwedt has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder, Allergan, Amgen, Avanir, Cipla, Dr. Reddy’s Laboratories, Eli Lilly, Ipsen Bioscience, Novartis, Salvia, Teva, and XoC Pharmaceuticals. Dr. Schwedt has received personal compensation in an editorial capacity for Associate Editor for Headache and Cephalalgia journals. Dr. Schwedt has received compensation for serving on the Board of Directors of Aural Analytics and Nocira. Dr. Schwedt has received research support from Amgen.
Check Point Inhibitors and Paraneoplastic Neurological Disorders
Start Time	Pub.	Title	Presenter
11:30 AM	005	Nivolumab-induced myasthenia gravis with myositis in patients with genitourinary cancer	Disclosure: Dr. Sun has nothing to disclose.
Unusual Stroke Etiologies, Presentations and Treatments
Start Time	Pub.	Title	Presenter
11:30 AM	005	Cerebral Fat Embolus (CFE): A Rare Cause of Multifocal Infarctions with Potential for Full Recovery	Disclosure: Dr. Taylor has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	005	Two Cases of Spinal Muscular Atrophy due to Mutations in the VRK1 Gene	Disclosure: Dr. Sung has nothing to disclose.
Epilepsy: EEG and Neurophysiology
Start Time	Pub.	Title	Presenter
11:30 AM	005	Age Norms of EEG during Sleep from 0 to 100 years old	Disclosure: Dr. Paixao has nothing to disclose.
Neuroepidemiology: ALS, MS, Parkinson's Disease and Epilepsy
Start Time	Pub.	Title	Presenter
11:30 AM	005	An Analysis of Free-text Responses by Individuals Enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry	Disclosure: Dr. Jordan has nothing to disclose.
Dystonia and Botulinum Toxin Therapy
Start Time	Pub.	Title	Presenter
11:30 AM	005	Neural Responses Are Abnormal During Reflexive Blinking in Blepharospasm: An Event-Related fMRI Study	Disclosure: Dr. Nguyen has nothing to disclose.
NeuroHIV and other Retroviruses
Start Time	Pub.	Title	Presenter
11:30 AM	005	Neurofilament Light Chain Protein Levels in HIV Positive Subjects with Neuropathy	Disclosure: Dr. Damian has nothing to disclose.
Aging and Dementia: Clinical Trials
Start Time	Pub.	Title	Presenter
11:30 AM	006	A Multidomain Precision Medicine Intervention in Patients at Risk for Dementia due to Alzheimer’s disease	Disclosure: Dr. Isaacson has nothing to disclose.
Movement Disorders ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	006	STN LFP and SUA characterization of dyskinesia in PD using microelectrode recordings	Disclosure: Dr. Jimenez Shahed has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with St. Jude Medical/Abbott, Medtronic, Boston Scientific, Teva, Bracket,Nuvelution, Sunovion,. Dr. Jimenez Shahed has received research support from Medtronic, St. Jude Medical/Abbott, Lily, Wilsons Therapeutics, Sunovion, Nuvelution.
Migraine II
Start Time	Pub.	Title	Presenter
11:30 AM	006	OnabotulinumtoxinA wear-off phenomenon in the treatment of chronic migraine	Disclosure: Dr. Masters-Israilov has nothing to disclose.
Check Point Inhibitors and Paraneoplastic Neurological Disorders
Start Time	Pub.	Title	Presenter
11:30 AM	006	Hunting the real culprit: a complex case of nivolumab-related myelitis.	Disclosure: Dr. Poretto has nothing to disclose.
Unusual Stroke Etiologies, Presentations and Treatments
Start Time	Pub.	Title	Presenter
11:30 AM	006	Tip-of-the-Basilar Stroke secondary to Fat Embolization after Hip Arthroplasty	Disclosure: Dr. Gopal has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	006	Oculomotor Dysfunction in Motor Neuron Disease	Disclosure: Dr. Lu has nothing to disclose.
Epilepsy: EEG and Neurophysiology
Start Time	Pub.	Title	Presenter
11:30 AM	006	EEG Source Imaging from Standard Long-term Video EEG Recording in Patients with Medically-refractory Focal Epilepsy	Disclosure: Dr. Cox has nothing to disclose.
Neuroepidemiology: ALS, MS, Parkinson's Disease and Epilepsy
Start Time	Pub.	Title	Presenter
11:30 AM	006	PRO-ACE: Global Collaborative Ecosystem in a Post-PRO-ACT Era	Disclosure: Dr. Sherman has nothing to disclose.
Dystonia and Botulinum Toxin Therapy
Start Time	Pub.	Title	Presenter
11:30 AM	006	Wireless, Wearable, Soft Electronics for Blepharospasm Assessment	Disclosure: Dr. Scorr has nothing to disclose.
NeuroHIV and other Retroviruses
Start Time	Pub.	Title	Presenter
11:30 AM	006	Inhibiting Mononuclear Phagocyte Functions in a HIV Associated Neurocognitive Disorders Mouse Model	Disclosure: Dr. Tyor has nothing to disclose.
Aging and Dementia: Clinical Trials
Start Time	Pub.	Title	Presenter
11:30 AM	007	Efficacy of Memantine Added to Cholinesterase Inhibitors on SIB Higher-Order Cognitive Domains: Pooled Post Hoc Analysis of 2 Randomized Controlled Trials in Patients With Moderate to Severe AD	Disclosure: Dr. Schmitt has received research support from NIH.
Movement Disorders ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	007	Gender disparities in deep brain stimulation surgery for Parkinson’s disease	Disclosure: Dr. Garbin Di Luca has nothing to disclose.
Migraine II
Start Time	Pub.	Title	Presenter
11:30 AM	007	'Sleep Disturbance and Environmental Reactivity as Potential Mechanisms for Comorbidity of Mood and Anxiety Disorders with Migraine	Disclosure: Dr. Lateef has nothing to disclose.
Check Point Inhibitors and Paraneoplastic Neurological Disorders
Start Time	Pub.	Title	Presenter
11:30 AM	007	Pembrolizumab-Induced Myasthenia Gravis	Disclosure: Dr. ALGaeed has nothing to disclose.
Unusual Stroke Etiologies, Presentations and Treatments
Start Time	Pub.	Title	Presenter
11:30 AM	007	Erythrocytapheresis: An emerging treatment option for cerebral fat embolism from hemoglobinopathy related bone marrow necrosis.	Disclosure: Dr. Siddiqui has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	007	Observational Quantitative Data in Adult Patients with SMA Dosed with Nusinersen	Disclosure: Dr. Burian has nothing to disclose.
Epilepsy: EEG and Neurophysiology
Start Time	Pub.	Title	Presenter
11:30 AM	007	Longitudinal Analysis of Interictal EEGs in Patients with TLE and Hippocampal Sclerosis	Disclosure: Dr. Brito has nothing to disclose.
Neuroepidemiology: ALS, MS, Parkinson's Disease and Epilepsy
Start Time	Pub.	Title	Presenter
11:30 AM	007	Forecasting Multiple Sclerosis Hospitalization and Healthcare Burden in the United States from 2017 to 2040	Disclosure: Dr. Sharma has nothing to disclose.
Dystonia and Botulinum Toxin Therapy
Start Time	Pub.	Title	Presenter
11:30 AM	007	Golfer’s Cramp: Effect of Propranolol and Looking at the Hole	Disclosure: Dr.Adler has received personal compensation for consulting serving on a scientific advisory board speaking or other activities with Acadia Jazz Neurocrine Scion and Sunovion.
NeuroHIV and other Retroviruses
Start Time	Pub.	Title	Presenter
11:30 AM	007	Occurrence of pneumocystis pneumonia in patients with neurological disease on immunosuppression: a single-center investigation	Disclosure: Dr. Li MD has nothing to disclose.
Aging and Dementia: Clinical Trials
Start Time	Pub.	Title	Presenter
11:30 AM	008	SIB Maintenance of Response With Memantine Added to Cholinesterase Inhibitors: Pooled Post Hoc Analysis of 2 Randomized Controlled Trials in Patients With Moderate to Severe AD	Disclosure: Dr. Schmitt has received research support from NIH.
Movement Disorders ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	008	Hyperglycemic Induced Chorea-Ballismus Responsive to Valbenazine: a Video Case Report and Review of the Literature.	Disclosure: Dr. Saunders has nothing to disclose.
Migraine II
Start Time	Pub.	Title	Presenter
11:30 AM	008	Methylation Analyses of Stress-Modified Genes in Migraine	Disclosure: Dr. Oterino Duran has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Almirall, Merck Serono, TEVA, Sanofi Genzyme, Allergan, MSD and Novartis. Dr. Oterino Duran has received research support from Sanofi Genzyme, Novartis.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	008	NFL pattern in progressive Multiple Sclerosis cohort under MD1003 treatment	Disclosure: Dr. Pignolet has nothing to disclose.
Unusual Stroke Etiologies, Presentations and Treatments
Start Time	Pub.	Title	Presenter
11:30 AM	008	Delayed Diagnosis of Fibrocartilaginous Embolism: Assessing the Vertebral Body on MRI	Disclosure: Dr. Isaac has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	008	Feasibility and Validation of Modified Oculobulbar Facial Respiratory Score (mOBFRS) in Amyotrophic Lateral Sclerosis	Disclosure: Dr. Goyal has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acceleron, Alexion, CSL Behring, and MT Pharma.
Epilepsy: EEG and Neurophysiology
Start Time	Pub.	Title	Presenter
11:30 AM	008	Quantitative EEG of Intracranial Recordings for Detection of Seizure Onset and Localization Compared to Standard Intracranial Tracing	Disclosure: Dr. Gangloff has nothing to disclose.
Neuroepidemiology: ALS, MS, Parkinson's Disease and Epilepsy
Start Time	Pub.	Title	Presenter
11:30 AM	008	Effects of cigarette smoking and smoking cessation on Multiple Sclerosis severity: a cross-sectional study	Disclosure: Dr. Ivashynka has nothing to disclose.
Dystonia and Botulinum Toxin Therapy
Start Time	Pub.	Title	Presenter
11:30 AM	008	Hand Motor Control in Patients with Cervical Dystonia: an fMRI Study	Disclosure: Dr. Hok has nothing to disclose.
NeuroHIV and other Retroviruses
Start Time	Pub.	Title	Presenter
11:30 AM	008	Minimal Effect on Cognitive Function Despite High Prevalence of Mental Health Disorders in Treated HIV	Disclosure: Dr. Horne has nothing to disclose.
Aging and Dementia: Clinical Trials
Start Time	Pub.	Title	Presenter
11:30 AM	009	Sildenafil Alters Hippocampal Fractional Amplitude of Low Frequency Fluctuations (fALFF) in Patients with Alzheimer’s Disease	Disclosure: Dr. Samudra has nothing to disclose.
Movement Disorders ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	009	Gait Analysis of GBA Mutation Carriers with Parkinson’s Disease	Disclosure: Dr. Gera has nothing to disclose.
Migraine II
Start Time	Pub.	Title	Presenter
11:30 AM	009	Healthcare Expenditure in Migraine Compared to Other Leading Causes of Disability: Adequate or Not?	Disclosure: Dr. Schaetz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis Pharma AG, Switzerland.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	009	Longitudinal stability of anti–JC virus (JCV) antibody index over 2 years in multiple sclerosis (MS) patients treated with natalizumab in the ASCEND study	Disclosure: Dr Mason is an employee of Biogen and receives personal compensation for employment. Dr Mason is an employee of Biogen and has received stock options from Biogen. Dr Mason is an employee and held stock in Biogen.
Unusual Stroke Etiologies, Presentations and Treatments
Start Time	Pub.	Title	Presenter
11:30 AM	009	CNS Manifestations of Hemophagocytic Lymphohistiocytosis (HLH)	Disclosure: Dr. Edwards has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	009	Monitoring and promoting effectiveness and adherence to non-invasive ventilation in motor neurone disease using EncoreAnywhere telemonitoring: a pilot and feasibility, randomised controlled trial.	Disclosure: Dr. James has nothing to disclose.
Epilepsy: EEG and Neurophysiology
Start Time	Pub.	Title	Presenter
11:30 AM	009	Validation of a dry-electrode EEG recording system: Results of a multi-reader blinded comparison to standard EEG	Disclosure: Dr. Zarroli has nothing to disclose.
Neuroepidemiology: ALS, MS, Parkinson's Disease and Epilepsy
Start Time	Pub.	Title	Presenter
11:30 AM	009	An increase in the prevalence of Multiple Sclerosis has moved Kuwait to a high-risk zone	Disclosure: Dr. Alroughani has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer, Biogen, Biologix, Merck, Novartis, Roche and Sanofi. Dr. Alroughani has received research support from Biogen, Merck, Novartis, Roche and Sanofi.
Dystonia and Botulinum Toxin Therapy
Start Time	Pub.	Title	Presenter
11:30 AM	009	Cervical dystonia patient’s satisfaction level after 3 years of botulinum toxin treatment	Disclosure: Dr. Misra has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ipsen Pharma.
NeuroHIV and other Retroviruses
Start Time	Pub.	Title	Presenter
11:30 AM	009	Inflammatory HIV-associated progressive multifocal leukoencephalopathy associated with high CD4 count	Disclosure: Dr. Ding has nothing to disclose.
Aging and Dementia: Clinical Trials
Start Time	Pub.	Title	Presenter
11:30 AM	010	Metformin and Newer Oral Hypoglycemic Agents are Associated with Better Cognitive Test Performance Over Ten Years in Older Diabetic Men	Disclosure: Dr. Duarte has nothing to disclose.
Movement Disorders ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	010	Changes to Levodopa Daily Dose in Parkinson’s Disease (PD) Patients with Dyskinesia While on GocovriTM (Amantadine) Extended Release Capsules: a Two-Year Phase 3 Open Label Study Analysis	Disclosure: Dr. Isaacson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie, Acadia, Acorda, Adamas, Addex, Allergan, Amarantus, Avid, Axovant, AZTherapies, Biogen, Britannia, Eisai, Eli Lilly, Enterin, GE Healthcare, Impax, Intec Pharma, Ipsen, Kyowa, Lundbeck, Michael J. Fox Foundation, Neurocrine, NeuroDerm, NINDS/NIH, Parkinson Study Group, Pfizer, Pharma Two B, Roche, Sanofi, Sunovion, Teva, UCB, US WorldMeds, and Zambon. Dr. Isaacson has received research support from Abbvie, Acadia, Acorda, Adamas, Amarantus, Axovant, AZ Therapies, Benevolent, Biogen, Cavion, Eli Lilly, Enterin, Impax, Intec Pharma, Jazz, Ipsen, Kyowa, Lundbeck, Michael J. Fox Foundation, Neuroderm, Parkinson Study Group, Pfizer, Pharma2B, Roche, Sanofi, Sunovion, Teva, UCB, US WorldMeds.
Migraine II
Start Time	Pub.	Title	Presenter
11:30 AM	010	Message Framing to Determine Best Methods for Discussing Migraine Behavioral Treatments with Persons with Migraine.	Disclosure: Dr. Jalloh has nothing to disclose.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	010	Two Cases of Meningitis Associated with Ocrelizumab Therapy	Disclosure: Dr. Theriault has nothing to disclose.
Unusual Stroke Etiologies, Presentations and Treatments
Start Time	Pub.	Title	Presenter
11:30 AM	010	Secondary Polycythemia as an Uncommon Cause of Large Vessel Occlusion Resulting in Acute Ischemic Stroke	Disclosure: Dr. Mulpur has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	010	Accelerated Pathology in Chlorovirus (ATCV-1) Infected SOD1G93A Transgenic ALS Mice and Association of Increased Serum Anti-ATCV-1 IgG1 Subclass with ALS	Disclosure: Dr. Pattee has nothing to disclose.
Epilepsy: EEG and Neurophysiology
Start Time	Pub.	Title	Presenter
11:30 AM	010	Surface-Electromyography (sEMG) Patterns of Clonic Bursts during Generalized Tonic-Clonic (GTC) Seizures	Disclosure: Dr. Cardenas has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Brain Sentinel.
Dystonia and Botulinum Toxin Therapy
Start Time	Pub.	Title	Presenter
11:30 AM	010	Basal Ganglia and Cerebellar Circuits Have Distinct Roles in Blepharospasm	Disclosure: Dr. Glickman has nothing to disclose.
NeuroHIV and other Retroviruses
Start Time	Pub.	Title	Presenter
11:30 AM	010	Thrombotic thrombocytopenic purpura (TTP) presenting with severe neurological manifestations in a patient with well-controlled HIV-1	Disclosure: Dr. Kimbrough has nothing to disclose.
Aging and Dementia: Clinical Trials
Start Time	Pub.	Title	Presenter
11:30 AM	011	Long-Term Efficacy for Parkinsonism and Safety of Zonisamide in Patients with Dementia with Lewy Bodies: A Phase III Trial	Disclosure: Dr. Toya has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sumitomo Dainippon Pharma Co., Ltd.
Migraine II
Start Time	Pub.	Title	Presenter
11:30 AM	011	A Randomized Controlled Trial to Assess the Effect of Telephone Based Motivational Interviewing on the Initiation and Adherence to Behavioral Therapy for Migraine	Disclosure: Dr. Minen has nothing to disclose.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	011	Fingolimod related cryptococcal meningitis and immune reconstitution inflammatory syndrome in two patients with multiple sclerosis	Disclosure: Dr. Cuascut Lassus has nothing to disclose.
Unusual Stroke Etiologies, Presentations and Treatments
Start Time	Pub.	Title	Presenter
11:30 AM	011	Multiterritorial ischemic strokes in idiopathic hypereosinophilic syndrome	Disclosure: Dr. Lee has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	011	Brain White Matter MRI Differentiates Kennedy’s Disease from Other Motor Neuron Disease Clinical Phenotypes	Disclosure: Dr. Spinelli has nothing to disclose.
Epilepsy: EEG and Neurophysiology
Start Time	Pub.	Title	Presenter
11:30 AM	011	In the kingdom of triphasic waves, white matter is the eminence grise	Disclosure: Dr. Kotchetkov has nothing to disclose.
Neuroepidemiology: ALS, MS, Parkinson's Disease and Epilepsy
Start Time	Pub.	Title	Presenter
11:30 AM	011	Lewy body dementia (LBD) prevalence and cholinesterase inhibitor use in Florida	Disclosure: Dr. Patel has nothing to disclose.
NeuroHIV and other Retroviruses
Start Time	Pub.	Title	Presenter
11:30 AM	011	Immune Reconstitution Inflammatory Syndrome in a newly diagnosed patient with HIV and Central Nervous System Tuberculosis (TB)	Disclosure: Dr. Abu-hadid has nothing to disclose.
Aging and Dementia: Clinical Trials
Start Time	Pub.	Title	Presenter
11:30 AM	012	Long-term Efficacy of Zonisamide on Parkinsonism in Dementia with Lewy Bodies: A Post-hoc Analysis of Phase 3 Trial	Disclosure: Dr. Takai has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sumitomo Dainippon Pharma Co., Ltd.
Migraine II
Start Time	Pub.	Title	Presenter
11:30 AM	012	Exploring Natural Cohorts of Chronic Migraine Phenotype	Disclosure: Dr. Woldeamanuel has nothing to disclose.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	012	Leprosy in two patients with Relapsing Remitting Multiple Sclerosis (RRMS) treated with Fingolimod	Disclosure: Dr. Balasa has nothing to disclose.
Unusual Stroke Etiologies, Presentations and Treatments
Start Time	Pub.	Title	Presenter
11:30 AM	012	Acute Ischemic Stroke in Cancer Patients. A Case-Control Study	Disclosure: Dr. Pappolla has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	012	Nusinersen for spinal muscular atrophy - results of an expanded access programme	Disclosure: Dr. Mazurkiewicz Beldzin has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Biomarin.
Epilepsy: EEG and Neurophysiology
Start Time	Pub.	Title	Presenter
11:30 AM	012	Diagnostic Utility of Continuous sEMG Monitoring in a Home Setting - Real-world use of the SPEAC® System	Disclosure: Dr. Whitmire has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Brain Sentinel.
Neuroepidemiology: ALS, MS, Parkinson's Disease and Epilepsy
Start Time	Pub.	Title	Presenter
11:30 AM	012	Vision loss in Parkinson’s disease: prevalence and association with outcomes among Medicare beneficiaries	Disclosure: Dr. Hamedani has nothing to disclose.
Dystonia and Botulinum Toxin Therapy
Start Time	Pub.	Title	Presenter
11:30 AM	012	Immunogenicity of DaxibotulinumtoxinA for Injection in Adults with Cervical Dystonia from a Phase 2 Dose-Escalation Multicenter Study	Disclosure: Dr. Brashear has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ipsen and Revance. Dr. Brashear has received research support from Wake Forest.
NeuroHIV and other Retroviruses
Start Time	Pub.	Title	Presenter
11:30 AM	012	PML presenting as an isolated vertigo: a diagnositic challange	Disclosure: Dr. Moustafa has nothing to disclose.
Aging and Dementia: Clinical Trials
Start Time	Pub.	Title	Presenter
11:30 AM	013	Transcranial Direct Current Stimulation Improves Verbal Fluency in Patients with Primary Progressive Aphasia	Disclosure: Dr. Hosseini has nothing to disclose.
Migraine II
Start Time	Pub.	Title	Presenter
11:30 AM	013	Risk of Worse Short-term Outcomes Associated with hospitalization for migraine and co-morbid psychiatric illness: A Nationwide Population-Based Cohort Study	Disclosure: Dr. Savani has nothing to disclose.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	013	Dimethyl Fumarate Dose Reduction in Lymphopenic Relapsing Remitting Multiple Sclerosis Patients: Clinical and MRI Outcomes	Disclosure: Dr. Wong has nothing to disclose.
Unusual Stroke Etiologies, Presentations and Treatments
Start Time	Pub.	Title	Presenter
11:30 AM	013	Prudent testing of factor V Leiden in Ischemic stroke	Disclosure: Dr. Kovi has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	013	Fat mass loss correlates with survival in amyotrophic lateral sclerosis patients: prospective cohort study	Disclosure: Dr. Lee has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alexion.
Epilepsy: EEG and Neurophysiology
Start Time	Pub.	Title	Presenter
11:30 AM	013	Is There a Role for Magnetoencephalography in Pre-surgical RNS Implantation in Drug-Resistant Temporal Lobe Epilepsy?	Disclosure: Dr. Alshammaa has nothing to disclose.
Neuroepidemiology: ALS, MS, Parkinson's Disease and Epilepsy
Start Time	Pub.	Title	Presenter
11:30 AM	013	Risk of readmission for injury in patients with epilepsy in the US	Disclosure: Dr. Goldstein has nothing to disclose.
Dystonia and Botulinum Toxin Therapy
Start Time	Pub.	Title	Presenter
11:30 AM	013	Implementation of the current dystonia classification from 2013 to 2017	Disclosure: Dr. Albanese has nothing to disclose.
NeuroHIV and other Retroviruses
Start Time	Pub.	Title	Presenter
11:30 AM	013	An Unusual Case of Multiple-Ring-Enhancing Lesions on Brain MRI in Varicella Zoster Virus Encephalitis	Disclosure: Dr. Hasan has nothing to disclose.
Neurovirology
Start Time	Pub.	Title	Presenter
11:30 AM	014	Hepatitis E virus infection and posterior reversible encephalopathy syndrome: a case report and review of the literature.	Disclosure: Dr. Loggini has nothing to disclose.
Aging and Dementia: Clinical Trials
Start Time	Pub.	Title	Presenter
11:30 AM	014	Safety and Efficacy of Medical Cannabis in Elderly Patients: A Retrospective Review in a Neurological Outpatient Setting.	Disclosure: Dr. Bargnes has received research support from Dent Family Foundation.
Migraine II
Start Time	Pub.	Title	Presenter
11:30 AM	014	Angiotensin Receptor Blockers and ACE Inhibitors for Migraine Prophylaxis - A Systematic Review	Disclosure: Dr. Dorosh has nothing to disclose.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	014	Infectious Risk Stratification in Multiple Sclerosis Patients Receiving Immunotherapy – An Update	Disclosure: Dr. Graf has nothing to disclose.
Unusual Stroke Etiologies, Presentations and Treatments
Start Time	Pub.	Title	Presenter
11:30 AM	014	An Uncommon Cause of Multifocal Intracerebral Hemorrhages: Adult-Onset Leukoencephalopathy with Calcifications and Cysts	Disclosure: Dr. Pyatka has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	014	Validation of a staging system in ALS: Comparison of the US and European Populations	Disclosure: Dr. Kwan has nothing to disclose.
Epilepsy: EEG and Neurophysiology
Start Time	Pub.	Title	Presenter
11:30 AM	014	Glossokinetic Potentials: Insights from intracranial EEG	Disclosure: Dr. Kacar Bayram has nothing to disclose.
Neuroepidemiology: ALS, MS, Parkinson's Disease and Epilepsy
Start Time	Pub.	Title	Presenter
11:30 AM	014	Characteristics of periventricular nodules in patients with 22q11. 2 deletion syndrome	Disclosure: Dr. Rezazadeh has nothing to disclose.
Dystonia and Botulinum Toxin Therapy
Start Time	Pub.	Title	Presenter
11:30 AM	014	A dopa-responsive dystonia-Parkinsonism-cerebellar syndrome associated with GCH1 gene mutation.	Disclosure: Dr. Garrett has nothing to disclose.
Neurovirology
Start Time	Pub.	Title	Presenter
11:30 AM	015	Abulia: A case of Powassan Encephalitis	Disclosure: Dr. Yalcin has nothing to disclose.
Aging and Dementia: Clinical Trials
Start Time	Pub.	Title	Presenter
11:30 AM	015	Intranasal Glulisine in Down Syndrome: A Pilot Safety and Tolerability Trial	Disclosure: Dr. Rosenbloom has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Paul Weiss. Dr. Rosenbloom has received research support from Merck Foundation.
Migraine II
Start Time	Pub.	Title	Presenter
11:30 AM	015	Effect of Galcanezumab on Severity of Headache and Associated Symptoms of Migraine in Phase 3 Trials in Patients with Episodic or Chronic Migraine	Disclosure: Dr. Day has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Employee of Eli Lilly and Company.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	015	Evaluating the Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Infusion Related Reactions in Relapsing Forms of Multiple Sclerosis	Disclosure: Dr. Alvarez has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with consulting fees from Actelion, Bayer, Biogen, Celgene, EMD Serono, Genentech, Genzyme, Novartis, and TG Therapeutics. Dr. Alvarez has received research support from Biogen, Genentech, Novartis, TG Therapeutics, and Rocky Mountain MS Center.
Unusual Stroke Etiologies, Presentations and Treatments
Start Time	Pub.	Title	Presenter
11:30 AM	015	Lacunar Strokes in Cryptococcal Meningitis: Clinical and Radiographic Features in a U.S. Cohort	Disclosure: Dr. Vela-Duarte has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	015	Nusinersen in Adults with Spinal Muscular Atrophy, A Single Center Experience	Disclosure: Dr. Moshe-Lilie has nothing to disclose.
Epilepsy: EEG and Neurophysiology
Start Time	Pub.	Title	Presenter
11:30 AM	015	Ictal urinary urgency localized by Stereo-electroencephalogram.	Disclosure: Dr. Murray-Frank has nothing to disclose.
Neuroepidemiology: Stroke, Critical Care, Headache and Global Health
Start Time	Pub.	Title	Presenter
11:30 AM	015	Cognitive decline after a mild or moderate stroke and TIA: evidence from the SWIFT Trial	Disclosure: Dr. Boden-Albala has nothing to disclose.
Dystonia and Botulinum Toxin Therapy
Start Time	Pub.	Title	Presenter
11:30 AM	015	Assessment of standing balance by force plate posturography in X-linked Dystonia Parkinsonism (XDP)	Disclosure: Dr. Stephen has nothing to disclose.
Neurovirology
Start Time	Pub.	Title	Presenter
11:30 AM	016	West Nile encephalitis in a patient with initially negative CSF serology.	Disclosure: Dr. Sanmartin has nothing to disclose.
Migraine II
Start Time	Pub.	Title	Presenter
11:30 AM	016	Migraine and Cluster Headache Classification Using a Supervised Machine Learning Approach: A Multimodal MRI Study	Disclosure: Dr. Messina has nothing to disclose.
Aging and Dementia: Neuropsychology and Clinical Studies II
Start Time	Pub.	Title	Presenter
11:30 AM	016	Structured delirium care pathway is associated with reductions in length of stay, cost and readmissions in hospitalized adults	Disclosure: Dr. LaHue has nothing to disclose.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	016	A Rare Complication of Fingolimod: Case Report of Posterior Reversible Encephalopathy Syndrome	Disclosure: Dr. Downey Allison has nothing to disclose.
Unusual Stroke Etiologies, Presentations and Treatments
Start Time	Pub.	Title	Presenter
11:30 AM	016	Hypertension Increases Risk of Ischemic Stroke in Multiple Sclerosis: Retrospective Analysis of a National Database	Disclosure: Dr. Ikram has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	016	Spinal Muscular Atrophy: A Review of Epidemiology, Burden and Unmet Needs	Disclosure: Dr. Callan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis Ireland Ltd.
Epilepsy: EEG and Neurophysiology
Start Time	Pub.	Title	Presenter
11:30 AM	016	The Prognostic Value of Quantitative EEG in Patients Undergoing Mechanical Thrombectomy for Acute Ischemic Stroke	Disclosure: Dr. Dickey has nothing to disclose.
Neuroepidemiology: Stroke, Critical Care, Headache and Global Health
Start Time	Pub.	Title	Presenter
11:30 AM	016	Seasonal Variation in Stroke Incidence in Black versus White Medicare Beneficiaries	Disclosure: Dr. Baig has nothing to disclose.
Dystonia and Botulinum Toxin Therapy
Start Time	Pub.	Title	Presenter
11:30 AM	016	Botulinum toxin injection changes resting state cerebellar connectivity in cervical dystonia.	Disclosure: Dr. Nevrly has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with consultant for Medtronic.
Neurovirology
Start Time	Pub.	Title	Presenter
11:30 AM	017	A Bird Whisperer’s Tale: The unique occurrence of stroke as a precursor to diagnosing West Nile Meningoencephalitis.	Disclosure: Dr. Jacob has nothing to disclose.
Migraine II
Start Time	Pub.	Title	Presenter
11:30 AM	017	Acute Anti-Migraine Prescription Varies According to Baseline Cardiovascular Risk and Clinical Characteristics: A Real-World Evidence Study	Disclosure: Dr. Li has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Li holds stock and/or stock options in Eli Lilly and Company.
Aging and Dementia: Neuropsychology and Clinical Studies II
Start Time	Pub.	Title	Presenter
11:30 AM	017	Snow laughing matter: Delirium severity increases in winter months compared with summer months	Disclosure: Dr. Douglas has nothing to disclose.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	017	Among Real-world Multiple Sclerosis Patients That Experience Delayed-release Dimethyl Fumarate-associated Lymphopenia, Meaningful Lymphocyte Reconstitution Occurs Approximately 3 Months After Discontinuation of Delayed-release Dimethyl Fumarate	Disclosure: Dr. Rose has received research support from National Multiple Sclerosis Society, Guthy Jackson Foundation, NIH, Friends of MS, Western Institute for Biomedical Research, and Biogen.
Unusual Stroke Etiologies, Presentations and Treatments
Start Time	Pub.	Title	Presenter
11:30 AM	017	Fabry disease and Stroke: Effectiveness of Enzyme Replacement Therapy (ERT) in Stroke Prevention, a Review with Meta-Analysis	Disclosure: Dr. Sheng has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	017	Determinants of Mortality Among Hospitalized Patients with Amyotrophic Lateral Sclerosis – Results from the 2016 National Inpatient Sample	Disclosure: Dr. L'Italien has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biohaven Pharmaceuticals. Dr. L'Italien holds stock and/or stock options in Biohaven Pharmaceuticals which sponsored research in which Dr. L'Italien was involved as an investigator. Dr. L'Italien holds stock and/or stock options in Biohaven Pharmaceuticals. Dr. L'Italien has received research support from Biohaven Pharmaceuticals.
Epilepsy: EEG and Neurophysiology
Start Time	Pub.	Title	Presenter
11:30 AM	017	Wearable Sensors for the Detection of Convulsive Seizures	Disclosure: Dr. McGinn has nothing to disclose.
Neuroepidemiology: Stroke, Critical Care, Headache and Global Health
Start Time	Pub.	Title	Presenter
11:30 AM	017	Disparities, Predictors and Trends of Left Atrial Appendage Closure Among Hospitalized Patients with Atrial Fibrillation in the United States	Disclosure: Dr. Badi has nothing to disclose.
Dystonia and Botulinum Toxin Therapy
Start Time	Pub.	Title	Presenter
11:30 AM	017	Jaw Opening Oromandibular Dystonia following Acute Stroke: Analysis and Review	Disclosure: Dr. Singhvi has nothing to disclose.
Neurovirology
Start Time	Pub.	Title	Presenter
11:30 AM	018	Case Series: Congenital Zika Virus Infection associated with Epileptic Spasms	Disclosure: Dr. Diaz Diaz has nothing to disclose.
Migraine II
Start Time	Pub.	Title	Presenter
11:30 AM	018	Work Activities Associated with Migraine: Results from Migraine in America Symptoms and Treatment (MAST) Study	Disclosure: Dr. Alam has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr. Reddy’s Laboratories group of companies.
Aging and Dementia: Neuropsychology and Clinical Studies II
Start Time	Pub.	Title	Presenter
11:30 AM	018	Identifying Common Themes in ICU Deaths of Patients with a Diagnosis of Alzheimer Disease	Disclosure: Dr. Grant has nothing to disclose.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	018	No significant risk of malignant melanoma growth under cladribine treatment: in vitro studies	Disclosure: Dr. Berestjuk has nothing to disclose.
Unusual Stroke Etiologies, Presentations and Treatments
Start Time	Pub.	Title	Presenter
11:30 AM	018	Sickle Cell Trait and Risk for Early-Onset Ischemic Stroke	Disclosure: Dr. Zhang has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	018	Analysis of nutritional status as a predictor of survival in patients with bulbar amyotrophic lateral sclerosis (ALS)	Disclosure: Dr. Bettini has nothing to disclose.
Epilepsy: EEG and Neurophysiology
Start Time	Pub.	Title	Presenter
11:30 AM	018	The Use of Collodion versus Traditional Paste for Reducing Artifact in Ambulatory Electroencephalography Studies in the Pediatric Population	Disclosure: Dr. Brigham has nothing to disclose.
Neuroepidemiology: Stroke, Critical Care, Headache and Global Health
Start Time	Pub.	Title	Presenter
11:30 AM	018	Comparing the Outcomes of Patients with Idiopathic Subarachnoid Hemorrhage by Three Distinct Perimesencephalic Bleed Patterns	Disclosure: Dr. Wagner has nothing to disclose.
Dystonia and Botulinum Toxin Therapy
Start Time	Pub.	Title	Presenter
11:30 AM	018	ATP1A3 Gene Mutations Associated with Rapid-Onset Dystonia-Parkinsonism (RDP) Presenting with Functional Neurologic Disorder: A Report of Two Cases	Disclosure: Dr. Biller has nothing to disclose.
Neurovirology
Start Time	Pub.	Title	Presenter
11:30 AM	019	The Diagnosis of Pseudorabies Virus Encephalitis and Endophthalmitis by Next Generation Sequencing in Two Chinese Pork Retailers	Disclosure: Dr. Liu has nothing to disclose.
Migraine II
Start Time	Pub.	Title	Presenter
11:30 AM	019	Triptan Use and Discontinuation in a Representative Sample of Persons With Migraine: Results From Migraine in America Symptoms and Treatment (MAST) Study	Disclosure: Dr. Alam has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr. Reddy’s Laboratories group of companies.
Aging and Dementia: Neuropsychology and Clinical Studies II
Start Time	Pub.	Title	Presenter
11:30 AM	019	Caregiver Depression and Emergency Department Utilization in Dementia	Disclosure: Dr. Guterman has nothing to disclose.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	019	Serious Adverse Events in Rituximab-Treated Patients with Multiple Sclerosis and Related Disorders	Disclosure: Dr. Wallach has received research support from Biogen.
Unusual Stroke Etiologies, Presentations and Treatments
Start Time	Pub.	Title	Presenter
11:30 AM	019	Degos' disease: the hint is in the skin	Disclosure: Dr. Calame has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	019	Dextromethorphan-Quinidine (Nuedexta) Improves Swallowing in Bulbar Onset ALS Patients with Pseudobulbar Affect - Pre-Post Observational Study in 86 ALS Patients	Disclosure: Dr. Shah has nothing to disclose.
Epilepsy: EEG and Neurophysiology
Start Time	Pub.	Title	Presenter
11:30 AM	019	An Effective Tool for Teaching EEG Interpretation to Residents and Medical Students	Disclosure: Dr. Hubert has nothing to disclose.
Neuroepidemiology: Stroke, Critical Care, Headache and Global Health
Start Time	Pub.	Title	Presenter
11:30 AM	019	Time Trends, Race Disparities, and Administration of Intravenous Thrombolysis for Acute Ischemic Stroke: A Statewide Study	Disclosure: Dr. Marszalek has nothing to disclose.
Dystonia and Botulinum Toxin Therapy
Start Time	Pub.	Title	Presenter
11:30 AM	019	Pilot trial of botulinum toxin and occupational therapy for Writer’s Cramp	Disclosure: Dr. Park has nothing to disclose.
Neurovirology
Start Time	Pub.	Title	Presenter
11:30 AM	020	An unusual case of feline-transmitted Rabies: A Diagnostic and Preventative Approach.	Disclosure: Dr. Escobar-Montealegre has nothing to disclose.
Migraine II
Start Time	Pub.	Title	Presenter
11:30 AM	020	Prophylactic Use of SNRIs to Treat Pediatric Migraine via Reduction of Comorbid Anxiety and Depression	Disclosure: Dr. McAlister has nothing to disclose.
Aging and Dementia: Neuropsychology and Clinical Studies II
Start Time	Pub.	Title	Presenter
11:30 AM	020	The Lived Experience of Lay Caregivers Caring for Persons with Dementia	Disclosure: Dr. Mayo has nothing to disclose.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	020	Central Nervous System T Cell Lymphoproliferative Disease Following Treatment with Alemtuzumab	Disclosure: Dr. Horton has nothing to disclose.
Unusual Stroke Etiologies, Presentations and Treatments
Start Time	Pub.	Title	Presenter
11:30 AM	020	Diagnostic Challenges in Vascular Myelopathies	Disclosure: Dr. Passeri has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	020	Structural and Functional Organization of the Brain Connectome in Patients with Different Motor Neuron Diseases: A Multicenter Study	Disclosure: Dr. Agosta has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis.
Epilepsy: EEG and Neurophysiology
Start Time	Pub.	Title	Presenter
11:30 AM	020	Case Report: Change in Electrocorticogram Detection of RNS with Initiation of Ketogenic Diet	Disclosure: Dr. Greenwood has nothing to disclose.
Neuroepidemiology: Stroke, Critical Care, Headache and Global Health
Start Time	Pub.	Title	Presenter
11:30 AM	020	For Men Only, High Hematocrit Values Are Associated With Stroke In The Young	Disclosure: Dr. Bartt has nothing to disclose.
Dystonia and Botulinum Toxin Therapy
Start Time	Pub.	Title	Presenter
11:30 AM	020	Identifying Reliable Measures of Impairment in Focal Hand Dystonia Patients	Disclosure: Dr. Bukhari-Parlakturk has nothing to disclose.
Neurovirology
Start Time	Pub.	Title	Presenter
11:30 AM	021	An Uncommon Case of Treatment-Responsive SSPE	Disclosure: Dr. Hocquard has nothing to disclose.
Migraine II
Start Time	Pub.	Title	Presenter
11:30 AM	021	Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene?Related Peptide Receptor	Disclosure: Dr. Moore has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck & Co., Inc. Dr. Moore holds stock and/or stock options in Merck & Co., Inc which sponsored research in which Dr. Moore was involved as an investigator.
Aging and Dementia: Neuropsychology and Clinical Studies II
Start Time	Pub.	Title	Presenter
11:30 AM	021	Real World Treatment of Parkinson’s Disease Dementia (PDD) in the United States (U.S.)	Disclosure: Dr. Schroeder has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Schroeder holds stock and/or stock options in Eli Lilly and Company which sponsored research in which Dr. Schroeder was involved as an investigator. .
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	021	Risk factors for Development of Lymphopenia in Dimethyl Fumarate-treated Patients with Multiple Sclerosis	Disclosure: Dr. Bloch has nothing to disclose.
Unusual Stroke Etiologies, Presentations and Treatments
Start Time	Pub.	Title	Presenter
11:30 AM	021	Isolated Cervical Anterior Spinal Artery Aneurysms (CASAAs): A Case Series and The Comprehensive Outcome Analysis of surgical vs non-surgical interventions	Disclosure: Dr. SirDeshpande has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	021	CX3CL1 Disruption Differentially Influences the Neuroprotective Effects of Mesenchymal Stromal Cells on ALS	Disclosure: Dr. Huang has nothing to disclose.
Epilepsy: EEG and Neurophysiology
Start Time	Pub.	Title	Presenter
11:30 AM	021	Correlation of Indicators of P300 Cognitive Potentials with Epilepsy Forms	Disclosure: Dr. Salokhiddinov has nothing to disclose.
Neuroepidemiology: Stroke, Critical Care, Headache and Global Health
Start Time	Pub.	Title	Presenter
11:30 AM	021	Systematic Characterization of Large Vessel Occlusion Strokes at a CSC	Disclosure: Dr. Desai has nothing to disclose.
Dystonia and Botulinum Toxin Therapy
Start Time	Pub.	Title	Presenter
11:30 AM	021	Indications, Outcomes and Cost of pediatric Deep Brain Stimulation Surgeries in the United States: An Analysis of the Kids’ Inpatient Sample	Disclosure: Dr. Akano has nothing to disclose.
Neurovirology
Start Time	Pub.	Title	Presenter
11:30 AM	022	West Nile Virus Neuroinvasive Disease Associated with Rituximab Therapy	Disclosure: Dr. Owens has nothing to disclose.
Migraine II
Start Time	Pub.	Title	Presenter
11:30 AM	022	Response to Lasmiditan for Acute Treatment of Migraine Based on Prior Response to Triptan Therapy	Disclosure: Dr. Knievel has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Consulting for Amgen, Lilly, Allergan, Biohaven. Speaking Amgen and Allergan.. Dr. Knievel has received research support from Allergan; Alder.
Aging and Dementia: Neuropsychology and Clinical Studies II
Start Time	Pub.	Title	Presenter
11:30 AM	022	MCI and OSA	Disclosure: Dr. Patel has nothing to disclose.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	022	Severe skin reactions associated with Cladribine treatment in patients with multiple sclerosis	Disclosure: Dr. Mateo-Casas has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with UCB Pharma, Sanofi-Genzyme.
Unusual Stroke Etiologies, Presentations and Treatments
Start Time	Pub.	Title	Presenter
11:30 AM	022	Intravascular Lymphoma Presenting with Spinal Cord Infarct and Recurrent Ischemic Strokes	Disclosure: Dr. Lyden has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	022	Adherence to Riluzole Therapy Improves Time to and Frequency of All Cause Hospitalization in ALS Patients: A Claims-Based Longitudinal Comparative Effectiveness Analysis.	Disclosure: Dr. L'Italien has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biohaven Pharmaceuticals. Dr. L'Italien holds stock and/or stock options in Biohaven Pharmaceuticals which sponsored research in which Dr. L'Italien was involved as an investigator. Dr. L'Italien holds stock and/or stock options in Biohaven Pharmaceuticals. Dr. L'Italien has received research support from Biohaven Pharmaceuticals.
Epilepsy: EEG and Neurophysiology
Start Time	Pub.	Title	Presenter
11:30 AM	022	Assessing Retinal Cytoarchitecture between Temporal Onset Focal and Primary Generalized Seizure Types Utilizing Optical Coherence Tomography	Disclosure: Dr. Lichtman-Mikol has nothing to disclose.
Neuroepidemiology: Stroke, Critical Care, Headache and Global Health
Start Time	Pub.	Title	Presenter
11:30 AM	022	Is Altitude Associated With Ischemic Stroke In The Young?	Disclosure: Dr. Salottolo has nothing to disclose.
Dystonia and Botulinum Toxin Therapy
Start Time	Pub.	Title	Presenter
11:30 AM	022	Kufor-Rakeb Syndrome with Prominent Dystonia and New Mutations in ATP13A2 Gene in Two Siblings	Disclosure: Dr. Yamasaki has nothing to disclose.
Neurovirology
Start Time	Pub.	Title	Presenter
11:30 AM	023	A Quality Improvement Project Studying the Integration of a Proposed Diagnostic Algorithm on Inpatient Encephalitis into the Electronic Medical Record and its Impact on Length of Hospital Stay	Disclosure: Dr. Kaplan has nothing to disclose.
Migraine II
Start Time	Pub.	Title	Presenter
11:30 AM	023	Impact of OnabotulinumtoxinA on Quality of Life, Health Resource Utilization, and Work Productivity in People With Chronic Migraine: Interim Results From a Prospective, Observational Study (PREDICT)	Disclosure: Dr. Boudreau has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Amgen, Lilly, and Teva. Dr. Boudreau has received research support from Allergan, Amgen, Lilly, and Teva.
Aging and Dementia: Neuropsychology and Clinical Studies II
Start Time	Pub.	Title	Presenter
11:30 AM	023	Vascular dementia in elderly .Population-based study in Matanzas.	Disclosure: Dr. Munoz Perez has nothing to disclose.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	023	Delayed-release Dimethyl Fumarate-associated Lymphopenia: On-treatment and Post-treatment Implications	Disclosure: Dr. Chan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer, Biogen, Genzyme, Merck, Novartis, Roche, Teva, Swiss National Fonds, Genzyme and UCB, Clinical and translational neuroscience and the Journal of International medical research. Dr. Chan has received research support from Bayer, Biogen, Genzyme, Merck, Novartis, Roche, Teva, Swiss National Fonds, Genzyme and UCB, Clinical and translational neuroscience and the Journal of International medical research.
Unusual Stroke Etiologies, Presentations and Treatments
Start Time	Pub.	Title	Presenter
11:30 AM	023	Simultaneous Epidural and Intramedullary Hemorrhage: A Case Report.	Disclosure: Dr. Shah has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	023	Diffusion Tension Imaging as the Biomarker for Amyotrophic Lateral Sclerosis	Disclosure: Dr. Baek has nothing to disclose.
Epilepsy: EEG and Neurophysiology
Start Time	Pub.	Title	Presenter
11:30 AM	023	Normalized transfer entropy used as an informational transfer measure of ictal pathophysiology in patients undergoing stereo-EEG for epilepsy surgery	Disclosure: Dr. Lee has received research support from America Epilepsy Society.
Neuroepidemiology: Stroke, Critical Care, Headache and Global Health
Start Time	Pub.	Title	Presenter
11:30 AM	023	Acute neurological complications after adult single and double lung transplant	Disclosure: Dr. Rauf has nothing to disclose.
Dystonia and Botulinum Toxin Therapy
Start Time	Pub.	Title	Presenter
11:30 AM	023	The Trend in Botulinum Toxin Injection among Medicare Neurology Providers in the United States from 2012 to 2016	Disclosure: Dr. Miri has nothing to disclose.
Neurovirology
Start Time	Pub.	Title	Presenter
11:30 AM	024	A simple bioinformatics approach to disentangle the etiology and prognosis of CNS infections	Disclosure: Dr. Tan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis, Merck, UCB, Sanofi Genzyme and Eisai.
Migraine II
Start Time	Pub.	Title	Presenter
11:30 AM	024	Eptinezumab Increases Days Free from Canonical Migraine-Associated Symptoms Within 1 Month of Treatment in Patients with Chronic Migraine	Disclosure: Dr. Schim has received personal compensation from the following companies: Consultant: Acorda, Alder, Allergan, Amgen, Avanir, Depomed, electroCore, Lilly, Novartis, Pernix, Promius, Supernus, Teva, Upsher-Smith Grant/research support: Alder, Allergan, Amgen, electroCore, Lilly, Teva Speaker: Acorda, Allergan, Amgen, Avanir, Depomed, electroCore, Lilly, Novartis, Pernix, Promius, Supernus, Teva, Upsher-Smith Grant/research support: Alder, Allergan, Amgen, electroCore, Lilly, Teva
Aging and Dementia: Neuropsychology and Clinical Studies II
Start Time	Pub.	Title	Presenter
11:30 AM	024	Characteristics of Young-onset and Late-onset Dementia Patients at a Rural and Remote Memory Clinic	Disclosure: Dr. Wong has nothing to disclose.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	024	Immunization and Multiple Sclerosis: Recommendations from the French Multiple Sclerosis Society	Disclosure: Dr. Lebrun Frenay has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi, Genzyme, Merck, Novartis, Biogen.
Unusual Stroke Etiologies, Presentations and Treatments
Start Time	Pub.	Title	Presenter
11:30 AM	024	Spinal Claudication Due to Anterior Disco-osteo-arterial Conflict Mimicking Stiff Person Syndrome	Disclosure: Dr. Murphy has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	024	Diminshed Muscle Oxygenation During Exercise in Ambulatory Spinal Muscular Atrophy Patients	Disclosure: Dr. Montes has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Astellas, Biogen, Cytokinetics, Roche, and Scholar Rock. Dr. Montes has received research support from MDA and NICHD / NIH.
Epilepsy: General Medical Issues, PNES, and Other
Start Time	Pub.	Title	Presenter
11:30 AM	024	The Relationship between Seizures, Ictal-Interictal EEG Activity, Clinical Outcome, and Dynamic Neurologic Changes following Traumatic Brain Injury	Disclosure: Dr. Edhi has nothing to disclose.
Neuroepidemiology: Stroke, Critical Care, Headache and Global Health
Start Time	Pub.	Title	Presenter
11:30 AM	024	Association between neurological syndromes and Arbovirus in Buenos Aires - Relationship between Guillain Barre Syndrome, Encephalitis and Myelitis with Zika, Dengue and Chikungunya	Disclosure: Dr. Kohler has nothing to disclose.
Dystonia and Botulinum Toxin Therapy
Start Time	Pub.	Title	Presenter
11:30 AM	024	RimabotulinumtoxinB (MYOBLOC) in the treatment of adult sialorrhea	Disclosure: Dr. Ondo has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with UCBPharma, TEVA, USWorldMeds, Neurocrine, and ADAMAS. Dr. Ondo has received research support from Lundbeck, Sunovian, and Neuroderm.
Neurovirology
Start Time	Pub.	Title	Presenter
11:30 AM	025	Evaluation of BioFire Film Array Meningitis/ Encephalitis (ME) panel in testing of CSF specimen of patients of meningoencephalitis in Indian scenario	Disclosure: Dr. Rohatgi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbott, Boehringer, Intas Pharma, Pfizer, Eisai, Genzyme, Sanofi, UCB, Cipla.
Migraine II
Start Time	Pub.	Title	Presenter
11:30 AM	025	Does the presence of Cranial Autonomic Symptoms in Chronic Migraine Patients Predict Efficacy of Botox Injections?	Disclosure: Dr. Riggins has nothing to disclose.
Aging and Dementia: Neuropsychology and Clinical Studies II
Start Time	Pub.	Title	Presenter
11:30 AM	025	Subjective Cognitive Impairment: A Clinical and neuropsychological Entity, sustained by a specific Topography of Lesions. The Cingulum Cohort of Marseille, France.	Disclosure: Dr. Sambuchi has nothing to disclose.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	025	Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients With Relapsing and Primary Progressive Multiple Sclerosis	Disclosure: Dr. Hauser has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Annexon, Symbiotix, Bionure and Neurona; he has also received travel reimbursement from F. Hoffmann-La Roche Ltd and Novartis for CD20-related meetings and presentation.
Unusual Stroke Etiologies, Presentations and Treatments
Start Time	Pub.	Title	Presenter
11:30 AM	025	Spinal Cord Infarction: A Diagnostic Challenge	Disclosure: Dr. Passeri has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	025	Population Based Surveillance and Survival Characteristics of Amyotrophic Lateral Sclerosis (ALS) Cases in the Atlanta Metropolitan Area, 2009 – 2011	Disclosure: Dr. Punjani MPH has nothing to disclose.
Epilepsy: General Medical Issues, PNES, and Other
Start Time	Pub.	Title	Presenter
11:30 AM	025	Seizures after Cardiovascular Surgery: An unexpected complication	Disclosure: Dr. Bolaño Diaz has nothing to disclose.
Neuroepidemiology: Stroke, Critical Care, Headache and Global Health
Start Time	Pub.	Title	Presenter
11:30 AM	025	Long-Term Outcomes of Guillain-Barre Syndrome Associated with Zika Virus Infection	Disclosure: Dr. Walteros has nothing to disclose.
Dystonia and Botulinum Toxin Therapy
Start Time	Pub.	Title	Presenter
11:30 AM	025	Individualized OnabotulinumtoxinA Treatment for Upper Limb Spasticity Resulted in High Patient and Clinician Satisfaction in the ASPIRE Study	Disclosure: Dr. Francisco has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Merz, and Ipsen. Dr. Francisco has received research support from Allergan, Merz, and Ipsen.
Neurovirology
Start Time	Pub.	Title	Presenter
11:30 AM	026	Progressive Multifocal Leukoencephalopathy in an Immunocompetent Patient: A Rare Case with Radiologic-Pathologic Correlation	Disclosure: Dr. Fecto has nothing to disclose.
Aging and Dementia: Neuropsychology and Clinical Studies II
Start Time	Pub.	Title	Presenter
11:30 AM	026	The Free and Cued Selective Reminding Test Predicts Alzheimer’s Disease Neuropathology	Disclosure: Dr. Grober has received royalty, license fees, or contractual rights payments from Albert Einstein College of Medicine.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	026	Influence of Clinical and Cerebrospinal Fluid Parameters on the Effect of Therapeutic Plasma Exchange in Patients with Multiple Sclerosis	Disclosure: Dr. Eienbröker has nothing to disclose.
Unusual Stroke Etiologies, Presentations and Treatments
Start Time	Pub.	Title	Presenter
11:30 AM	026	CADASIL in a Patient with Bilateral Internal Carotid Artery Agenesis	Disclosure: Dr. MacDonald has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	026	Factors Associated with Poor Compliance of Non-invasive Ventilator Support in Patients with ALS	Disclosure: Dr. Kohli has nothing to disclose.
Epilepsy: General Medical Issues, PNES, and Other
Start Time	Pub.	Title	Presenter
11:30 AM	026	Prognosis and Clinical Factors to Predict Seizure Recurrence in Patients with Alcohol-Related Seizures	Disclosure: Dr. Chun has nothing to disclose.
Neuroepidemiology: Stroke, Critical Care, Headache and Global Health
Start Time	Pub.	Title	Presenter
11:30 AM	026	The Pattern of Neurologic Disease in Tanzanian Tribal Populations	Disclosure: Dr. Aamodt has nothing to disclose.
Dystonia and Botulinum Toxin Therapy
Start Time	Pub.	Title	Presenter
11:30 AM	026	Individualized OnabotulinumtoxinA Treatment for Lower Limb Spasticity Resulted in High Patient and Clinician Satisfaction in the ASPIRE Study	Disclosure: Dr. Esquenazi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Ipsen, and Mertz. Dr. Esquenazi has received research support from Allergan and Ipsen.
Neurovirology
Start Time	Pub.	Title	Presenter
11:30 AM	027	A Case of Hepatitis E Transverse Myelitis	Disclosure: Dr. Doyle has nothing to disclose.
Aging and Dementia: Neuropsychology and Clinical Studies II
Start Time	Pub.	Title	Presenter
11:30 AM	027	Color Vision Impairment in Prodromal and Dementia Stages of Lewy Body Disease versus Alzheimer’s Disease	Disclosure: Dr. Unger has nothing to disclose.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	027	Cytomegalovirus (CMV) Primoinfection in a patient with Multiple Sclerosis treated with Alemtuzumab	Disclosure: Dr. Aguirre Hernandez has nothing to disclose.
Unusual Stroke Etiologies, Presentations and Treatments
Start Time	Pub.	Title	Presenter
11:30 AM	027	Rapidly progressive dementia with seizures due to venous hypertension from arteriovenous hemodialysis graft	Disclosure: Dr. Mazzola has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	027	Clinical Factors Predicting Cognitive Errors in The Misdiagnosis of Amyotrophic Lateral Sclerosis (ALS)	Disclosure: Dr. Gummi has nothing to disclose.
Epilepsy: General Medical Issues, PNES, and Other
Start Time	Pub.	Title	Presenter
11:30 AM	027	Acute Seizure Incidence in Ischemic Stroke Patients Treated with Mechanical retrieval therapy: A Single Center Study	Disclosure: Dr. Morris has nothing to disclose.
Neuroepidemiology: Stroke, Critical Care, Headache and Global Health
Start Time	Pub.	Title	Presenter
11:30 AM	027	Migraine and the Prevalence of Metabolic Syndrome among Women	Disclosure: Dr. Rist has received personal compensation in an editorial capacity for Stroke - a journal of the American Heart Association.
Dystonia and Botulinum Toxin Therapy
Start Time	Pub.	Title	Presenter
11:30 AM	027	Botulinum Toxin for the treatment of muscle spasms associated with Stiff Person Syndrome	Disclosure: Dr. Moukheiber has nothing to disclose.
Neurovirology
Start Time	Pub.	Title	Presenter
11:30 AM	028	Neuroinvasive West Nile Virus: a Case Series in Nebraska	Disclosure: Dr. Purbaugh has nothing to disclose.
Aging and Dementia: Neuropsychology and Clinical Studies II
Start Time	Pub.	Title	Presenter
11:30 AM	028	The Role of Population Receptive Fields' Size in Understanding Complex Visual Dysfunctions: Posterior Cortical Atrophy Model	Disclosure: Dr. De Best has nothing to disclose.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	028	Changes in the immune cell profile in fingolimod-treated patients with relapsing multiple sclerosis: primary analysis of the FLUENT study	Disclosure: Dr. Mao-Draayer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Accorda, Biogen, Bayer Pharmaceutical, Celgene, Teva, Genentech, Sanofi-Genzyme, Novartis, Chugai and EMD Serono. Dr. Mao-Draayer has received research support from NIH NIAID Autoimmune Center of Excellence, Sanofi-Genzyme, Novartis and Chugai.
Unusual Stroke Etiologies, Presentations and Treatments
Start Time	Pub.	Title	Presenter
11:30 AM	028	Recurrent Stroke in Giant Cell Arteritis Despite Immunotherapy	Disclosure: Dr. Cox has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	028	Facial Onset Sensory-Motor Neuronopathy: A Series of Two Cases Illustrating a Disease Spectrum	Disclosure: Dr. Yasin has nothing to disclose.
Epilepsy: General Medical Issues, PNES, and Other
Start Time	Pub.	Title	Presenter
11:30 AM	028	Postencephalitic Epilepsy and Acute Symptomatic Seizures, in Infectious, Undetermined Etiology and Autoimmune Encephalitis	Disclosure: Dr. Marone has nothing to disclose.
Child Neurology: Movement Disorders
Start Time	Pub.	Title	Presenter
11:30 AM	028	Genetic testing of >1300 patients with cerebral palsy reveals an etiology in one-third of cases, underscoring the need for broad genetic testing and a significant recurrence risk for families.	Disclosure: Dr. Millan Zamora has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with GeneDx.
Other Hyperkinetic Movement Disorders and Tremor
Start Time	Pub.	Title	Presenter
11:30 AM	028	Tremor in the Degenerative Cerebellum: Towards the Understanding of Brain Circuitry for Tremor	Disclosure: Dr. Kuo has nothing to disclose.
Neurovirology
Start Time	Pub.	Title	Presenter
11:30 AM	029	West Nile Virus Encephalitis Associated with Intraventricular Diffusion Restriction	Disclosure: Dr. Shetty has nothing to disclose.
Aging and Dementia: Neuropsychology and Clinical Studies II
Start Time	Pub.	Title	Presenter
11:30 AM	029	Quantification of Real-World Life Space from Instrumented Vehicles in Drivers with Cognitive Aging	Disclosure: Dr. Merickel has nothing to disclose.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	029	Multiple sclerosis treatment strategy after natalizumab-associated progressive multifocal leukoencephalopathy	Disclosure: Dr. Waheed has nothing to disclose.
Cerebrovascular Disease and Interventional Neurology: Vertebral and Basilar Artery Disease
Start Time	Pub.	Title	Presenter
11:30 AM	029	Outcomes of Mechanical Retrieval Therapy in Basilar Artery Occlusions: A Single Center Study	Disclosure: Dr. Hawkins has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	029	Frequency, Symptomology, and Course of HIV-Associated ALS: Case Series and Review	Disclosure: Dr. Satin has nothing to disclose.
Epilepsy: General Medical Issues, PNES, and Other
Start Time	Pub.	Title	Presenter
11:30 AM	029	Epilepsia Partialis Continua Secondary to Diabetic Ketoacidosis	Disclosure: Dr. Van Orman has nothing to disclose.
Child Neurology: Movement Disorders
Start Time	Pub.	Title	Presenter
11:30 AM	029	Evalualuation of Tremor in Childhood Electrophysiologically Influences Prognosis and Outcome	Disclosure: Dr. Lavenstein has nothing to disclose.
Other Hyperkinetic Movement Disorders and Tremor
Start Time	Pub.	Title	Presenter
11:30 AM	029	Cerebellar Structure in Patients with Parkinson’s Disease and Essential Tremor	Disclosure: Dr. Lopez has nothing to disclose.
Neurovirology
Start Time	Pub.	Title	Presenter
11:30 AM	030	A Case of Presumed Post-Transplant West Nile Virus Encephalitis without CSF Pleocytosis or IgM Positivity	Disclosure: Dr. Shetty has nothing to disclose.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	030	Increased Multiple Sclerosis disease activity in patients transitioned from fingolimod to dimethyl fumarate	Disclosure: Dr. Delgado has nothing to disclose.
Cerebrovascular Disease and Interventional Neurology: Vertebral and Basilar Artery Disease
Start Time	Pub.	Title	Presenter
11:30 AM	030	Outcomes of Acute Basilar Occlusion Ischemic Strokes with Advent of Modern Thrombectomy Devices, a New York State Experience	Disclosure: Dr. Vanguru has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	030	Primary Lateral Sclerosis (PLS) vs. Hereditary Spastic Paraperesis (HSP) in Presenilin-1 (PSEN1) related Dominant Dementia	Disclosure: Dr. Ahmadi Jazi has nothing to disclose.
Epilepsy: General Medical Issues, PNES, and Other
Start Time	Pub.	Title	Presenter
11:30 AM	030	Two Cases of Provoked Seizure Associated With Kratom Ingestion	Disclosure: Dr. Burke has nothing to disclose.
Child Neurology: Movement Disorders
Start Time	Pub.	Title	Presenter
11:30 AM	030	Alice in Wonderland Syndrome: Case Series and Analysis	Disclosure: Dr. Fine has nothing to disclose.
Other Hyperkinetic Movement Disorders and Tremor
Start Time	Pub.	Title	Presenter
11:30 AM	030	The importance of intra-operative assessment in VIM DBS for Tremor: Insights from 145 procedures	Disclosure: Dr. Mahajan has nothing to disclose.
Neurovirology
Start Time	Pub.	Title	Presenter
11:30 AM	031	Cerebrovascular manifestations of herpes simplex virus infection of the central nervous system: a systematic review	Disclosure: Dr. Sellner has nothing to disclose.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	031	The Marburg Multiple Sclerosis - Cohort — Loss of MEDA under two standard treatment sequences	Disclosure: Dr. Jurs has nothing to disclose.
Cerebrovascular Disease and Interventional Neurology: Vertebral and Basilar Artery Disease
Start Time	Pub.	Title	Presenter
11:30 AM	031	Thermoregulatory Dysfunction in a Patient with Locked-in Syndrome Due to Bilateral Ventral Pontine Infarction	Disclosure: Dr. Jordan has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	031	Multielectrode array analysis of human iPSC-motor neuron maturation following co-culture with iPSC- spinal cord astrocytes	Disclosure: Dr. Taga has nothing to disclose.
Epilepsy: General Medical Issues, PNES, and Other
Start Time	Pub.	Title	Presenter
11:30 AM	031	Medically Refractory Epilepsy Associated with Celiac Disease	Disclosure: Dr. Postelnik has nothing to disclose.
Child Neurology: Movement Disorders
Start Time	Pub.	Title	Presenter
11:30 AM	031	Neuropsychological Assessment In Patients With Alternating Hemiplegia Of Childhood (AHC)	Disclosure: Dr. Fernandes has nothing to disclose.
Other Hyperkinetic Movement Disorders and Tremor
Start Time	Pub.	Title	Presenter
11:30 AM	031	Risk Factors Causing Extended Hospitalizations due to Altered Arousal and Speech Dysfunction Following Deep Brain Stimulation for Essential Tremor	Disclosure: Dr. Anderson has nothing to disclose.
Neurovirology
Start Time	Pub.	Title	Presenter
11:30 AM	032	Super Refractory Status Epilepticus Secondary to La Crosse Virus Encephalitis: A Case Report	Disclosure: Dr. Mohl has nothing to disclose.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	032	Immunosuppresion following alemtuzumab in relapsing-remitting multiple sclerosis patients previously treated with fingolimod	Disclosure: Dr. Cabrera Maqueda has nothing to disclose.
Cerebrovascular Disease and Interventional Neurology: Vertebral and Basilar Artery Disease
Start Time	Pub.	Title	Presenter
11:30 AM	032	Outcome in Acute Basilar Artery Occlusion Based on Time and Severity at Presentation: A Retrospective Review	Disclosure: Dr. Suriya has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	032	Patient-Reported Outcomes Measures in Children with Spinal Muscular Atrophy	Disclosure: Dr. Risson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis Pharma AG, Basel, Switzerland.
Epilepsy: General Medical Issues, PNES, and Other
Start Time	Pub.	Title	Presenter
11:30 AM	032	Profile and Outcome of Psychogenic Nonepileptic Seizures Patients undergoing Video-EEG Monitoring	Disclosure: Dr. Wolfe has nothing to disclose.
Child Neurology: Movement Disorders
Start Time	Pub.	Title	Presenter
11:30 AM	032	Insights into Alternating Hemiplegia of Childhood from EEG Monitoring during an Episode, and Successful Prophylaxis with Levetiracetam	Disclosure: Dr. Mirzoev has nothing to disclose.
Other Hyperkinetic Movement Disorders and Tremor
Start Time	Pub.	Title	Presenter
11:30 AM	032	Distinguishing tremor components in Essential Tremor: a digital spirography study	Disclosure: Dr. Osterholt has nothing to disclose.
Neurovirology
Start Time	Pub.	Title	Presenter
11:30 AM	033	Unusual movement disorders and atypical MRI findings in patients with West Nile Encephalitis: A case series of two patients with evidence of clinical and imaging resolution with IVIG	Disclosure: Dr. Sheikh has nothing to disclose.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	033	PML Risk Perception in Patients Initiating Natalizumab for Multiple Sclerosis	Disclosure: Dr. Berkovich has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda, Avanir, Bayer, Biogen, Novartis, Questcor, Sanofi, and Teva. Dr. Berkovich has received research support from Acorda, Avanir, Bayer, Biogen, Novartis, Questcor, Sanofi, and Teva.
Cerebrovascular Disease and Interventional Neurology: Vertebral and Basilar Artery Disease
Start Time	Pub.	Title	Presenter
11:30 AM	033	Association of Functional Outcome in Basilar Artery Occlusion in Relation to Baseline Comorbidities: A Retrospective Review	Disclosure: Dr. Bzdyra has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	033	Co-existing riboflavin transporter deficiency (RTD) type 2 and muscle AMP deaminase deficiency in two long-term RTD survivors: report of a family	Disclosure: Dr. Zhang has nothing to disclose.
Epilepsy: General Medical Issues, PNES, and Other
Start Time	Pub.	Title	Presenter
11:30 AM	033	An Institutional Experience on Semiology of Psychogenic Nonepileptic Seizures	Disclosure: Dr. Fahimi has nothing to disclose.
Child Neurology: Movement Disorders
Start Time	Pub.	Title	Presenter
11:30 AM	033	A Very Rare Cause of a Common Tremor	Disclosure: Dr. Kabbani has nothing to disclose.
Other Hyperkinetic Movement Disorders and Tremor
Start Time	Pub.	Title	Presenter
11:30 AM	033	Cortical hyperexcitability in sialidosis type 1	Disclosure: Dr. Vial has nothing to disclose.
Neurovirology
Start Time	Pub.	Title	Presenter
11:30 AM	034	Elsberg Syndrome, The Often Missed Other Cauda Equina	Disclosure: Dr. Yogendran has nothing to disclose.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	034	Temporal profile of lymphocytes following treatment with cladribine tablets in patients switching from lymphocyte depleting or sequestering disease modifying drugs (DMDs)	Disclosure: Dr. Hodgkinson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck, Sanofi Genzyme, Novartis.
Cerebrovascular Disease and Interventional Neurology: Vertebral and Basilar Artery Disease
Start Time	Pub.	Title	Presenter
11:30 AM	034	Interrater Agreement for Measurements of Vertebral Artery Origin Stenosis	Disclosure: Dr. Bell has nothing to disclose.
Motor Neuron Disease
Start Time	Pub.	Title	Presenter
11:30 AM	034	Effect of Radicava on Uric Acid Levels: Preliminary Results	Disclosure: Dr. Heiman-Patterson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Cytokinetics, Mitsubishi Tanabe, PTC Therapeutics.
Epilepsy: General Medical Issues, PNES, and Other
Start Time	Pub.	Title	Presenter
11:30 AM	034	Serum Levels of Inflammasome Complex Factors are Suppressed in Focal Epilepsy Patients	Disclosure: Dr. Yavuz has nothing to disclose.
Child Neurology: Movement Disorders
Start Time	Pub.	Title	Presenter
11:30 AM	034	KMT2B early childhood onset dystonia presenting as failure to thrive	Disclosure: Dr. Ng has nothing to disclose.
Other Hyperkinetic Movement Disorders and Tremor
Start Time	Pub.	Title	Presenter
11:30 AM	034	Hyperkinetic Movement Disorders Associated With Immunosuppressant And Cefepime Use In Inpatients	Disclosure: Dr. Couto has nothing to disclose.
Neurovirology
Start Time	Pub.	Title	Presenter
11:30 AM	035	A 59-year-old Immunocompetent Man with Rapid Onset of Truncal Ataxia: A Case of Acute Cerebellitis Secondary to Varicella Zoster Virus.	Disclosure: Dr. Cross has nothing to disclose.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	035	Predicting Natalizumab Discontinuation due to Breakthrough Disease in Multiple Sclerosis Patients	Disclosure: Dr. Conway has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Arena pharmaceuticals. Dr. Conway has received personal compensation in an editorial capacity for Neurotherapeutics. Dr. Conway has received research support from Novartis Pharmaceuticals.
Cerebrovascular Disease and Interventional Neurology: Vertebral and Basilar Artery Disease
Start Time	Pub.	Title	Presenter
11:30 AM	035	Comparison Between Medical Therapy And Endovascular Treatment Of Extracranial Atherosclerotic Vertebral Artery Disease: A Systematic Review	Disclosure: Dr. Daniel has nothing to disclose.
Neurophysiology in Neuromuscular Disorders II
Start Time	Pub.	Title	Presenter
11:30 AM	035	Hybrid Recording System of Electromyography and Ultrasound in Neuromuscular Disorder	Disclosure: Dr. Sekiguchi has nothing to disclose.
Child Neurology: Neuroinflammatory Disease
Start Time	Pub.	Title	Presenter
11:30 AM	035	Cortical Abnormalities and Cognitive Impairment in Pediatric MS Patients	Disclosure: Dr. De Meo has nothing to disclose.
Other Hyperkinetic Movement Disorders and Tremor
Start Time	Pub.	Title	Presenter
11:30 AM	035	Effects of Concomitant Medication Use on Tardive Dyskinesia Outcomes in Long-Term Valbenazine Trials	Disclosure: Dr. Comella has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda Therapeutics, Allergan, Inc; Lundbeck Ltd.; Merz Pharmaceuticals;Acadia Pharmaceuticals; Ipsen Pharmaceuticals, Jazz Pharmaceuticals, Neurocrine Biosciences Inc., Revance Therapeutic, Sunovion., AEON Biopharma. She receives royalties from Cambridge, Wolters Kluwer. . Dr. Comella has received research support from Acorda, Revance, Merz, Eisai, Jazz Pharmacuetical.
Neurovirology
Start Time	Pub.	Title	Presenter
11:30 AM	036	Oculomeningoencephalomyeloradiculitis: A case of fulminant varicella zoster infection in the setting of systemic lupus erythematosus	Disclosure: Dr. Perrone has nothing to disclose.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	036	Skin Warts during Fingolimod Treatment in Patients with Multiple Sclerosis	Disclosure: Dr. Yamout has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer, Biogen, Genpharm, Genzyme, Merck-Serono, Novartis. Dr. Yamout has received research support from Bayer, Biogen, Merck-Serono, Novartis, Pfizer.
Cerebrovascular Disease and Interventional Neurology: Vertebral and Basilar Artery Disease
Start Time	Pub.	Title	Presenter
11:30 AM	036	Prevalence of Atherosclerotic Vertebrobasilar Disease in patients with Ischemic Stroke in an Argentinian cohort of patients	Disclosure: Dr. Bandeo has nothing to disclose.
Neurophysiology in Neuromuscular Disorders II
Start Time	Pub.	Title	Presenter
11:30 AM	036	Safety of Needle Electromyography in Critically Ill Intensive Care Unit (ICU) Patients	Disclosure: Dr. Nagarajan has nothing to disclose.
Epilepsy: General Medical Issues, PNES, and Other
Start Time	Pub.	Title	Presenter
11:30 AM	036	Spanish Epilepsy Education Available on the Web	Disclosure: Dr. Duron has received personal compensation for consulting serving on a scientific advisory board speaking or other activities with Epilepsy Foundation of Greater Los Angeles.
Child Neurology: Neuroinflammatory Disease
Start Time	Pub.	Title	Presenter
11:30 AM	036	Imaging analysis differentiates vascular versus inflammatory myelopathies in children	Disclosure: Dr. Garcia-Dominguez has nothing to disclose.
Other Hyperkinetic Movement Disorders and Tremor
Start Time	Pub.	Title	Presenter
11:30 AM	036	RECLAIM-DCP: A Randomized, Double-Blind, Placebo-Controlled Study of Deutetrabenazine for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents	Disclosure: Dr. Claassen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Neuroscience, Lundbeck, Acadia, AbbVie. Dr. Claassen has received research support from NIH/NINDS, Michael J. Fox Foundation, Huntington Disease Society of America, Vaccinex, AbbVie, Auspex Pharmaceuticals.
Neurovirology
Start Time	Pub.	Title	Presenter
11:30 AM	037	A Novel Case of Herpes Simplex Encephalitis Complicated by Cerebral Venous Thrombosis	Disclosure: Dr. Eibling has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with TrueLearn .
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	037	Limited Effects of Interferon ß-1a in an IgG-driven Model of Multiple Sclerosis Pathology	Disclosure: Dr. Bennett has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Viela Bio, Genentech, Alexion, Roche, Chugai, Frequency Therapeutics, Clene Neuroscience, and Reistone. Dr. Bennett has received royalty, license fees, or contractual rights payments from Pure Biologics. Dr. Bennett has received research support from Mallinckrodt, and EMD Serono.
Cerebrovascular Disease and Interventional Neurology: Vertebral and Basilar Artery Disease
Start Time	Pub.	Title	Presenter
11:30 AM	037	Second Generation Drug-Eluting Stents for Endovascular Treatment of Ostial Vertebral Artery Stenosis: A Single-Center Experience	Disclosure: Dr. Mendez Ruiz has nothing to disclose.
Child Neurology: Neuroinflammatory Disease
Start Time	Pub.	Title	Presenter
11:30 AM	037	Autoimmune encephalitis associated with N-type voltage-gated calcium channels in children: a case series	Disclosure: Dr. Kornitzer has nothing to disclose.
Other Hyperkinetic Movement Disorders and Tremor
Start Time	Pub.	Title	Presenter
11:30 AM	037	Diagnosis and Treatment Experiences in a Real-World Sample of Tourette Syndrome and Tic Disorder Sufferers	Disclosure: Dr. Malaty has received research support from Abbvie, Auspex, Biogen, Biotie, Impax, Intrepid, Lundbeck, Nuvelution, Pfizer, and Revance.
Neurovirology
Start Time	Pub.	Title	Presenter
11:30 AM	038	Neuroinvasive Spectrum of West Nile Virus.	Disclosure: Dr. Srinivas has nothing to disclose.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	038	Autoimmune Hemolytic Anemia after Treatment with Fingolimod: A Case Report	Disclosure: Dr. Husain has nothing to disclose.
Cerebrovascular Disease and Interventional Neurology: Vertebral and Basilar Artery Disease
Start Time	Pub.	Title	Presenter
11:30 AM	038	: Vertebral artery origin stenosis: systematic review of randomized clinical trials	Disclosure: Dr. Ezepue has nothing to disclose.
Neurophysiology in Neuromuscular Disorders II
Start Time	Pub.	Title	Presenter
11:30 AM	038	The Neurophysiology of Oxaliplatin Effects on Peripheral Nerve	Disclosure: Dr. Stecker has received royalty, license fees, or contractual rights payments from UPTODate.
Child Neurology: Neuroinflammatory Disease
Start Time	Pub.	Title	Presenter
11:30 AM	038	Autoimmune Glial Fibrillary Acidic Protein (GFAP) Astrocytopathy Following Herpes Simplex Encephalitis (HSE) in a pediatric patient	Disclosure: Dr. Handoko has nothing to disclose.
Other Hyperkinetic Movement Disorders and Tremor
Start Time	Pub.	Title	Presenter
11:30 AM	038	Self-Reported Substance Use in a Real-World Sample of Subjects with Tourette Syndrome and Other Tic Disorder.	Disclosure: Dr. Deeb has received research support from Tools4Patients.
Neurovirology
Start Time	Pub.	Title	Presenter
11:30 AM	039	Post-operative HSV-2 Encephalitis Following Temporal Lobe Resection for Glioblastoma Multiforme	Disclosure: Dr. Mingbunjerdsuk has nothing to disclose.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	039	Longitudinal analysis of Peripheral Blood Mononuclear Cells in Lymphopenic and Non-lymphopenic Relapsing-Remitting Multiple Sclerosis (RRMS) patients treated with Dimethyl Fumarate	Disclosure: Dr. Nakhaei-Nejad has nothing to disclose.
Stroke Genetics and Epidemiology
Start Time	Pub.	Title	Presenter
11:30 AM	039	Concerning Temporal Trends in Transient Ischemic Attack Hospitalization	Disclosure: Dr. Sahawneh has nothing to disclose.
Neurophysiology in Neuromuscular Disorders II
Start Time	Pub.	Title	Presenter
11:30 AM	039	Increased Incidence of Martin Gruber Anastomosis in Individuals with Ulnar Neuropathy	Disclosure: Dr. Gandhy has nothing to disclose.
Child Neurology: Neuroinflammatory Disease
Start Time	Pub.	Title	Presenter
11:30 AM	039	Unilateral Primary CNS Vasculitis in a Child Associated with Increased ICP and Treated with Maximal Medical Therapy and Decompressive Hemicraniectomy	Disclosure: Dr. Wang has nothing to disclose.
Other Hyperkinetic Movement Disorders and Tremor
Start Time	Pub.	Title	Presenter
11:30 AM	039	Physical activity, sleep and tic severity in children	Disclosure: Dr. Pringsheim has nothing to disclose.
Neurovirology
Start Time	Pub.	Title	Presenter
11:30 AM	040	Acute Myositis in Three Adult Men with Rapid Resolution	Disclosure: Dr. Danielson has nothing to disclose.
MS Therapeutics: MOA and Safety
Start Time	Pub.	Title	Presenter
11:30 AM	040	Stability of JC Virus Index over Time – a Five Year Retrospective Study.	Disclosure: Dr. Gaughan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche, Novartis, Abbvie, Biogen. Dr. Gaughan has received research support from Roche via Newman Fellowship, University College Dublin.
Stroke Genetics and Epidemiology
Start Time	Pub.	Title	Presenter
11:30 AM	040	Healthcare Utilization Prior to Fatal Stroke Admission: Nationally Representative Data	Disclosure: